Redox active plasma iron in C282Y/C282Y hemochromatosis

被引:116
作者
Le Lan, C
Loréal, O
Cohen, T
Ropert, M
Glickstein, H
Lainé, F
Pouchard, M
Deugnier, Y
Le Treut, A
Breuer, W
Cabantchik, ZI
Brissot, P [1 ]
机构
[1] Univ Hosp Pontchaillou, Serv Malad Foie, F-35033 Rennes, France
[2] Univ Hosp Pontchaillou, INSERM, U522, F-35033 Rennes, France
[3] Univ Hosp Pontchaillou, Lab Biochim Gen & Enzymol, F-35033 Rennes, France
[4] Ctr Examen Sante CPAM, Rennes, France
[5] Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91905 Jerusalem, Israel
关键词
D O I
10.1182/blood-2004-09-3468
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Labile plasma iron (LPI) represents the redox active component of non-transferrin-bound iron (NTBI). Its presence in thalassemic patients has been recently reported. The aim of the present study was to quantify LPI in HFE genetic hemochromatosis (GH) and to characterize the mechanisms accounting for its appearance. We studied 159 subjects subdivided into the following groups: (1) 23 with iron overloaded GH; (2) 14 with iron-depleted GH; (3) 26 with dysmetabolic hepatosiderosis; (4) 33 with alcoholic cirrhosis; (5) 63 healthy controls. Both NTBI and LPI were substantially higher in patients with iron-overloaded GH than in those with iron-depleted GH or in healthy controls. LPI was significantly correlated with serum transaminase increase in this group. LPI was elevated in the alcoholic cirrhosis subgroup of severely affected patients. LPI was found essentially when transferrin saturation exceeded 75%, regardless of the etiologic condition. Transferrin saturation above 75% was related to iron overload in GH and to liver failure in alcoholic cirrhosis. LPI is present in C282Y/C282Y hemochromatosis and may be a marker of toxicity due to its potential for catalyzing the generation of reactive oxygen radicals in vivo.
引用
收藏
页码:4527 / 4531
页数:5
相关论文
共 28 条
[1]  
BARRY M, 1971, LANCET, V1, P100
[2]   A fluorescence-based one-step assay for serum non transferrin-bound iron [J].
Breuer, W ;
Cabantchik, ZI .
ANALYTICAL BIOCHEMISTRY, 2001, 299 (02) :194-202
[3]   Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy [J].
Breuer, W ;
Ermers, MJJ ;
Pootrakul, P ;
Abramov, A ;
Hershko, C ;
Cabantchik, ZI .
BLOOD, 2001, 97 (03) :792-798
[4]  
Brissot P, 2002, ADV EXP MED BIOL, V509, P45
[5]   ASCORBIC-ACID STATUS IN IDIOPATHIC HEMOCHROMATOSIS [J].
BRISSOT, P ;
DEUGNIER, Y ;
LETREUT, A ;
REGNOUARD, F ;
SIMON, M ;
BOUREL, M .
DIGESTION, 1978, 17 (06) :479-487
[6]   Clinical aspects of hemochromatosis [J].
Brissot, P ;
Guyader, D ;
Loréal, O ;
Lainé, F ;
Guillygomarc'h, A ;
Moirand, R ;
Deugnier, Y .
TRANSFUSION SCIENCE, 2000, 23 (03) :193-200
[7]   Oxidative status and malondialdehyde in β-thalassaemia patients [J].
Cighetti, G ;
Duca, L ;
Bortone, L ;
Sala, S ;
Nava, I ;
Fiorelli, G ;
Cappellini, MD .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2002, 32 :55-60
[8]   Non-transferrin-bound iron in alcohol abusers [J].
De Feo, TM ;
Fargion, S ;
Duca, L ;
Cesana, BM ;
Boncinelli, L ;
Lozza, P ;
Cappellini, MD ;
Fiorelli, G .
ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH, 2001, 25 (10) :1494-1499
[9]   Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients [J].
Espósito, BP ;
Breuer, W ;
Slotki, I ;
Cabantchik, ZI .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2002, 32 :42-49
[10]   Labile plasma iron in iron overload: redox activity and susceptibility to chelation [J].
Esposito, BP ;
Breuer, W ;
Sirankapracha, P ;
Pootrakul, P ;
Hershko, C ;
Cabantchik, ZI .
BLOOD, 2003, 102 (07) :2670-2677